BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 10346910)

  • 21. The drug-binding pocket of the human multidrug resistance P-glycoprotein is accessible to the aqueous medium.
    Loo TW; Bartlett MC; Clarke DM
    Biochemistry; 2004 Sep; 43(38):12081-9. PubMed ID: 15379547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Competitive and non-competitive inhibition of the multidrug-resistance-associated P-glycoprotein ATPase--further experimental evidence for a multisite model.
    Garrigos M; Mir LM; Orlowski S
    Eur J Biochem; 1997 Mar; 244(2):664-73. PubMed ID: 9119038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective modulation of P-glycoprotein-mediated drug resistance.
    Bebawy M; Morris MB; Roufogalis BD
    Br J Cancer; 2001 Dec; 85(12):1998-2003. PubMed ID: 11747345
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cholesterol-mediated activation of P-glycoprotein: distinct effects on basal and drug-induced ATPase activities.
    Belli S; Elsener PM; Wunderli-Allenspach H; Krämer SD
    J Pharm Sci; 2009 May; 98(5):1905-18. PubMed ID: 18937360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The reconstituted P-glycoprotein multidrug transporter is a flippase for glucosylceramide and other simple glycosphingolipids.
    Eckford PD; Sharom FJ
    Biochem J; 2005 Jul; 389(Pt 2):517-26. PubMed ID: 15799713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drugs transported by P-glycoprotein inhibit a 40 pS outwardly rectifying chloride channel.
    Bear CE
    Biochem Biophys Res Commun; 1994 Apr; 200(1):513-21. PubMed ID: 7909435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells.
    Wan CK; Zhu GY; Shen XL; Chattopadhyay A; Dey S; Fong WF
    Biochem Pharmacol; 2006 Sep; 72(7):824-37. PubMed ID: 16889754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. P-glycoprotein (ABCB1) interacts directly with lipid-based anti-cancer drugs and platelet-activating factors.
    Eckford PD; Sharom FJ
    Biochem Cell Biol; 2006 Dec; 84(6):1022-33. PubMed ID: 17215888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents.
    Pascaud C; Garrigos M; Orlowski S
    Biochem J; 1998 Jul; 333 ( Pt 2)(Pt 2):351-8. PubMed ID: 9657975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phospholipid flippase activity of the reconstituted P-glycoprotein multidrug transporter.
    Romsicki Y; Sharom FJ
    Biochemistry; 2001 Jun; 40(23):6937-47. PubMed ID: 11389609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The polar nature of 7-ketocholesterol determines its location within membrane domains and the kinetics of membrane microsolubilization by apolipoprotein A-I.
    Massey JB; Pownall HJ
    Biochemistry; 2005 Aug; 44(30):10423-33. PubMed ID: 16042420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug transport by reconstituted P-glycoprotein in proteoliposomes. Effect of substrates and modulators, and dependence on bilayer phase state.
    Lu P; Liu R; Sharom FJ
    Eur J Biochem; 2001 Mar; 268(6):1687-97. PubMed ID: 11248688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A mechanism for P-glycoprotein-mediated apoptosis as revealed by verapamil hypersensitivity.
    Karwatsky J; Lincoln MC; Georges E
    Biochemistry; 2003 Oct; 42(42):12163-73. PubMed ID: 14567677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. P glycoprotein and the mechanism of multidrug resistance.
    Váradi A; Szakács G; Bakos E; Sarkadi B
    Novartis Found Symp; 2002; 243():54-65; discussion 65-8, 180-5. PubMed ID: 11990782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nucleotide binding to the multidrug resistance P-glycoprotein as studied by ESR spectroscopy.
    Delannoy S; Urbatsch IL; Tombline G; Senior AE; Vogel PD
    Biochemistry; 2005 Oct; 44(42):14010-9. PubMed ID: 16229490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential interactions of cytochalasins with P-glycoprotein.
    Zilfou JT; Smith CD
    Oncol Res; 1995; 7(9):435-43. PubMed ID: 8835287
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Strength of Ca(2+) binding to retinal lipid membranes: consequences for lipid organization.
    Huster D; Arnold K; Gawrisch K
    Biophys J; 2000 Jun; 78(6):3011-8. PubMed ID: 10827979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detergents as intrinsic P-glycoprotein substrates and inhibitors.
    Li-Blatter X; Nervi P; Seelig A
    Biochim Biophys Acta; 2009 Oct; 1788(10):2335-44. PubMed ID: 19631191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pumping of drugs by P-glycoprotein: a two-step process?
    Litman T; Skovsgaard T; Stein WD
    J Pharmacol Exp Ther; 2003 Dec; 307(3):846-53. PubMed ID: 14534356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chalcogenopyrylium dyes as inhibitors/modulators of P-glycoprotein in multidrug-resistant cells.
    Sawada GA; Raub TJ; William Higgins J; Brennan NK; Moore TM; Tombline G; Detty MR
    Bioorg Med Chem; 2008 Nov; 16(22):9745-56. PubMed ID: 18849167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.